KR20140020840A - 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도 - Google Patents

허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20140020840A
KR20140020840A KR1020137015640A KR20137015640A KR20140020840A KR 20140020840 A KR20140020840 A KR 20140020840A KR 1020137015640 A KR1020137015640 A KR 1020137015640A KR 20137015640 A KR20137015640 A KR 20137015640A KR 20140020840 A KR20140020840 A KR 20140020840A
Authority
KR
South Korea
Prior art keywords
ischemia
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137015640A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 비. 바구이시
레이니에 비우웨스
랄프 카사레
스티븐 에이. 케이트
알란 에스. 라더
Original Assignee
이쉐믹스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이쉐믹스 엘엘씨 filed Critical 이쉐믹스 엘엘씨
Publication of KR20140020840A publication Critical patent/KR20140020840A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020137015640A 2010-11-18 2011-11-10 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도 Ceased KR20140020840A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US41524110P 2010-11-18 2010-11-18
US41524010P 2010-11-18 2010-11-18
US61/415,240 2010-11-18
US61/415,241 2010-11-18
US201161478310P 2011-04-22 2011-04-22
US61/478,310 2011-04-22
US201161500974P 2011-06-24 2011-06-24
US61/500,974 2011-06-24
PCT/US2011/060259 WO2012067947A1 (en) 2010-11-18 2011-11-10 Lipoyl compounds and their use for treating ischemic injury

Publications (1)

Publication Number Publication Date
KR20140020840A true KR20140020840A (ko) 2014-02-19

Family

ID=45217651

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137015640A Ceased KR20140020840A (ko) 2010-11-18 2011-11-10 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도

Country Status (15)

Country Link
US (2) US8815937B2 (https=)
EP (1) EP2640423B1 (https=)
JP (3) JP2014502264A (https=)
KR (1) KR20140020840A (https=)
CN (1) CN103561770B (https=)
AU (1) AU2011329215C1 (https=)
BR (1) BR112013012057B1 (https=)
CA (1) CA2817362C (https=)
DK (1) DK2640423T3 (https=)
ES (1) ES2640474T3 (https=)
IL (1) IL226258A (https=)
MX (1) MX344933B (https=)
NZ (1) NZ610378A (https=)
SG (1) SG190794A1 (https=)
WO (1) WO2012067947A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
DK2640423T3 (en) 2010-11-18 2017-10-02 Ischemix Llc LIPOYL COMPOUNDS AND THEIR USE IN TREATMENT OF ISchemic DAMAGE
ITFI20120170A1 (it) * 2012-08-28 2014-03-01 Consorzio Interuniversitario Nazion Ale Per La Sci Nuovi composti ad azione anti-allodinica ed anti-iperalgesica.
EP3110800A1 (en) * 2014-02-27 2017-01-04 Consorzio Interuniversitario Nazionale Per La Scienza E La Tecnologia Dei Materiali (INSTM) Novel compounds having anti-allodynic and antihyperalgesic activity
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
EP4018997A1 (en) * 2016-03-14 2022-06-29 NeoStrata Company, Inc. N-lipoic -amino acid or peptide, derivatives and their uses
RU2657820C1 (ru) * 2017-03-13 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ 4-(4-Ацетоксибензоиламино)бутаноилглицин, обладающий церебропротекторным действием при ишемии головного мозга
AU2018258158A1 (en) 2017-04-25 2019-11-21 Ischemix Llc Compositions and methods for treating traumatic brain injury
US20240124520A1 (en) * 2019-10-16 2024-04-18 The Board Of Trustees Of The Leland Stanford Junior University N-acylated histidine dipeptides as anticancer agents
US11306076B2 (en) * 2020-05-11 2022-04-19 Xi'an Taikomed Pharmaceutical Technology Co., Ltd. Silibinin lipoic acid ester with hepatoprotective activity and a method of preparing the same
CN116199666B (zh) * 2023-03-07 2025-02-28 中国药科大学 两亲性化合物及其药物组合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5288706A (en) 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
DE59010810D1 (de) 1989-11-09 1998-04-16 Asta Medica Ag Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
CA2118496C (en) 1992-04-24 2005-01-11 Roger Randall Charles New Method of reducing microorganism adhesion
WO1997000889A1 (en) 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides binding to low-density lipoproteins
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
CA2264485A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH11269170A (ja) * 1997-04-02 1999-10-05 Sankyo Co Ltd ジチオラン誘導体
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
CA2389429C (en) 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
EP1371640B1 (en) 2001-03-19 2009-10-28 Senju Pharmaceutical Co., Ltd. Novel a-lipoic acid derivative and use thereof
JP2005515156A (ja) 2001-05-25 2005-05-26 セレメディックス,インク. 反応性酸素種およびフリーラジカルの効力を中和するための単一アミノ酸に基づく化合物
JP4259813B2 (ja) * 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
WO2003055853A1 (en) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1476440A4 (en) 2002-02-22 2005-06-01 Albany College Of Pharmacy METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
EP1726596A4 (en) 2004-02-18 2009-08-26 Japan Science & Tech Agency SUGAR CHAIN LIGAND COMPOSITE COMPOUND AND PROCESS FOR PROTEIN ANALYSIS WITH THE LIGAND COMPOSITE COMPOUND
JP2006022066A (ja) * 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
JP2012508165A (ja) * 2008-11-07 2012-04-05 イスティテュート ビオキーミコ ナッツィオナーレ サーヴィオ エスアールエル α−リポ酸誘導体及び薬物製剤へのそれらの使用
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
EP3069612A3 (en) * 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
EP2821405B1 (en) * 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
DK2640423T3 (en) 2010-11-18 2017-10-02 Ischemix Llc LIPOYL COMPOUNDS AND THEIR USE IN TREATMENT OF ISchemic DAMAGE
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds

Also Published As

Publication number Publication date
CN103561770B (zh) 2016-11-09
JP2016033157A (ja) 2016-03-10
CN103561770A (zh) 2014-02-05
DK2640423T3 (en) 2017-10-02
MX344933B (es) 2017-01-11
US20150065564A1 (en) 2015-03-05
AU2011329215C1 (en) 2016-08-11
CA2817362A1 (en) 2012-05-24
IL226258A0 (en) 2013-07-31
EP2640423A1 (en) 2013-09-25
WO2012067947A1 (en) 2012-05-24
ES2640474T3 (es) 2017-11-03
JP2018016652A (ja) 2018-02-01
US9359325B2 (en) 2016-06-07
EP2640423B1 (en) 2017-07-26
IL226258A (en) 2017-02-28
BR112013012057B1 (pt) 2021-11-09
CA2817362C (en) 2018-10-23
BR112013012057A2 (pt) 2020-08-04
JP6280094B2 (ja) 2018-02-14
MX2013005508A (es) 2013-07-17
US8815937B2 (en) 2014-08-26
AU2011329215A1 (en) 2013-05-30
SG190794A1 (en) 2013-07-31
AU2011329215B2 (en) 2016-04-28
US20130237483A1 (en) 2013-09-12
JP2014502264A (ja) 2014-01-30
NZ610378A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
KR20140020840A (ko) 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도
ES2470673T3 (es) Composiciones y métodos para el tratamiento de la isquemia y de la lesión por isquemia y reperfusi�n
JP2003528146A (ja) 脳血管疾患の治療
KR20140092228A (ko) 지질-저하 항당뇨제
ES2441800T3 (es) Sales de ácido 3-pentilfenilacético y usos farmacéuticos de las mismas
JP2018502915A (ja) 炎症及び疼痛の治療のための組成物及び方法
JP2022521119A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
JP2919870B2 (ja) 肝障害抑制剤
JP2642198B2 (ja) 胃粘膜障害治療剤
JP2019203007A (ja) Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩
HK1189803A (en) Lipoyl compounds and their use for treating ischemic injury
HK1189803B (en) Lipoyl compounds and their use for treating ischemic injury
RS53896B1 (sr) Pantenil dokosaheksaenoat i njegova upotreba za lečenje i prevenciju kardiovaskularnih oboljenja
JP2022504584A (ja) Tca回路中間体およびその使用方法
JP5079503B2 (ja) ラジカルスカベンジャー及び活性酸素消去剤
JP2001506594A (ja) 医薬製剤
JP2023141229A (ja) 高リン血症治療用医薬用組成物
JPH03157385A (ja) 細胞防護剤
US20050165112A1 (en) Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
HK1167082B (en) Compositions and methods for treating ischemia and ischemia-reperfusion injury

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160831

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170828

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180730

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180228

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180911

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180829

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180730

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180228

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170828

X601 Decision of rejection after re-examination